B & T Capital Management DBA Alpha Capital Management Acquires 750 Shares of Kenvue Inc. (NYSE:KVUE)

B & T Capital Management DBA Alpha Capital Management lifted its position in Kenvue Inc. (NYSE:KVUE) by 0.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 197,958 shares of the company’s stock after purchasing an additional 750 shares during the quarter. B & T Capital Management DBA Alpha Capital Management’s holdings in Kenvue were worth $4,579,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Kenvue by 12.0% in the 1st quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock worth $3,579,294,000 after buying an additional 17,908,497 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Kenvue by 23.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock valued at $2,887,773,000 after buying an additional 25,238,112 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Kenvue by 9.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 79,863,967 shares of the company’s stock valued at $1,451,927,000 after buying an additional 7,023,047 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Kenvue by 6.7% in the fourth quarter. Wellington Management Group LLP now owns 76,501,956 shares of the company’s stock valued at $1,647,087,000 after purchasing an additional 4,815,126 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Kenvue by 11.1% in the first quarter. JPMorgan Chase & Co. now owns 68,319,998 shares of the company’s stock valued at $1,466,147,000 after purchasing an additional 6,825,611 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Price Performance

Shares of KVUE traded down $0.19 during mid-day trading on Thursday, hitting $21.34. The company’s stock had a trading volume of 3,918,129 shares, compared to its average volume of 18,214,293. The firm has a 50-day moving average price of $21.97 and a 200 day moving average price of $20.17. The stock has a market capitalization of $40.86 billion, a price-to-earnings ratio of 27.60, a PEG ratio of 2.92 and a beta of 1.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $23.55.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. The firm had revenue of $4 billion during the quarter, compared to analysts’ expectations of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company’s revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.32 earnings per share. On average, research analysts predict that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, August 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.84%. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s dividend payout ratio is currently 105.13%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Jefferies Financial Group assumed coverage on Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price on the stock. Citigroup lowered their price objective on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Piper Sandler raised their target price on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada downgraded shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research note on Tuesday, September 24th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average price target of $22.10.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.